Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.
Lab Med
; 52(5): 493-498, 2021 Sep 01.
Article
in English
| MEDLINE | ID: covidwho-1526169
ABSTRACT
OBJECTIVE:
The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19.METHODS:
We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated.RESULTS:
Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001).CONCLUSION:
We found that MR-proADM could represent a prognostic biomarker of COVID-19.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Protein Precursors
/
Adrenomedullin
/
COVID-19
/
Hypertension
/
Lung Diseases
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Lab Med
Year:
2021
Document Type:
Article
Affiliation country:
Labmed
Similar
MEDLINE
...
LILACS
LIS